NCT03326063View on ClinicalTrials.gov

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

March 30, 2022

Study Completion Date

April 15, 2023

Conditions
Nasal PolypsAsthma, Aspirin-InducedAspirin-exacerbated Respiratory DiseaseAspirin-Sensitive Asthma With Nasal Polyps
Interventions
DRUG

Ifetroban

4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD

DRUG

Placebo

4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD

Trial Locations (1)

02115

Asthma Research Center, Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban | Biotech Hunter | Biotech Hunter